Brain Cancer Treatments – Extreme Drug Resistance
Learn More About Brain Cancer Extreme Drug Resistance: Chat with Us | Email Us
Extreme Drug Resistance for Brain Cancer
At Cancer Treatment Centers of America (CTCA), we tailor your brain cancer treatment plan to your specific needs. One of the innovative ways CTCA cancer experts customize your brain cancer treatment is by using the Extreme Drug Resistance (EDR) Assay (also known as chemoresistance).
A highly accurate test for solid brain cancer tumors, the EDR assay is used to determine the probability of a tumor’s resistance to a specific chemotherapy drug. If tumor cells continue to grow while in the presence of extreme exposure to a certain chemotherapy drug, it indicates significant drug resistance. Thus, if a tumor is resistant to a drug in an EDR assay, then the actual tumor in the body will most likely be resistant to that drug.
By testing for drug resistance prior to initiating therapy, the Extreme Drug Resistance Assay can help CTCA physicians avoid unnecessary toxicity to you, minimize costs, and consider other brain cancer treatment protocols.
Next Topic: MRI for Brain Cancer
